A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia.

If a dose demonstrated a predictive probability of .10 that the final P value of the ABT-126 dose versus placebo would be ≤.05 for three consecutive interim evaluations or the predictive probabilities showed a decreasing trend for three consecutive evaluations with the last evaluation reaching the threshold of .10, then no additional subjects would have been enrolled in that dose group.

also in 47,180 other papers